Skip to main content
  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

AACR logo

  • Register
  • Log in
  • My Cart
Advertisement

Main menu

  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

  • AACR Publications
    • Blood Cancer Discovery
    • Cancer Discovery
    • Cancer Epidemiology, Biomarkers & Prevention
    • Cancer Immunology Research
    • Cancer Prevention Research
    • Cancer Research
    • Clinical Cancer Research
    • Molecular Cancer Research
    • Molecular Cancer Therapeutics

User menu

  • Register
  • Log in
  • My Cart

Search

  • Advanced search
Cancer Prevention Research
Cancer Prevention Research
  • Home
  • About
    • The Journal
    • AACR Journals
    • Subscriptions
    • Permissions and Reprints
    • Reviewing
  • Articles
    • OnlineFirst
    • Current Issue
    • Past Issues
    • Meeting Abstracts
    • Collections
      • COVID-19 & Cancer Resource Center
      • "Best of" Collection
      • Editors' Picks
  • For Authors
    • Information for Authors
    • Author Services
    • Best of: Author Profiles
    • Submit
  • Alerts
    • Table of Contents
    • Editors' Picks
    • OnlineFirst
    • Citation
    • Author/Keyword
    • RSS Feeds
    • My Alert Summary & Preferences
  • News
    • Cancer Discovery News
  • COVID-19
  • Webinars
  • Search More

    Advanced Search

Research Article

6-Shogaol from Dried Ginger Inhibits Growth of Prostate Cancer Cells Both In Vitro and In Vivo through Inhibition of STAT3 and NF-κB Signaling

Achinto Saha, Jorge Blando, Eric Silver, Linda Beltran, Jonathan Sessler and John DiGiovanni
Achinto Saha
1Division of Pharmacology and Toxicology and 2Department of Nutritional Sciences, Dell Pediatric Research Institute; and 3Department of Chemistry, The University of Texas at Austin, Austin, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jorge Blando
1Division of Pharmacology and Toxicology and 2Department of Nutritional Sciences, Dell Pediatric Research Institute; and 3Department of Chemistry, The University of Texas at Austin, Austin, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Eric Silver
1Division of Pharmacology and Toxicology and 2Department of Nutritional Sciences, Dell Pediatric Research Institute; and 3Department of Chemistry, The University of Texas at Austin, Austin, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Linda Beltran
1Division of Pharmacology and Toxicology and 2Department of Nutritional Sciences, Dell Pediatric Research Institute; and 3Department of Chemistry, The University of Texas at Austin, Austin, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Jonathan Sessler
1Division of Pharmacology and Toxicology and 2Department of Nutritional Sciences, Dell Pediatric Research Institute; and 3Department of Chemistry, The University of Texas at Austin, Austin, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John DiGiovanni
1Division of Pharmacology and Toxicology and 2Department of Nutritional Sciences, Dell Pediatric Research Institute; and 3Department of Chemistry, The University of Texas at Austin, Austin, Texas
1Division of Pharmacology and Toxicology and 2Department of Nutritional Sciences, Dell Pediatric Research Institute; and 3Department of Chemistry, The University of Texas at Austin, Austin, Texas
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
DOI: 10.1158/1940-6207.CAPR-13-0420 Published June 2014
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

Article Figures & Data

Figures

  • Additional Files
  • Figure 1.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 1.

    6-SHO inhibits cell survival and induces apoptosis in human prostate cancer cells. A, LNCaP, DU145, and PC-3 cells were treated with the indicated concentrations of 6-SHO for 24, 48, and 72 hours and cell survival was measured by MTT assay. The data are presented as mean±SEM. B, cells were treated with vehicle or 40 μmol/L 6-SHO for 48 hours and apoptosis was measured by Annexin V staining. The data are presented as mean±SEM. C, cells were treated with vehicle or 6-SHO for 24 hours and Western blot analysis was performed for apoptosis markers. a, significantly different (P < 0.05) compared with the control group and (b) compared with the other treated groups. Changes in relative band intensities (normalized to β-actin) for Western blot data in C are given at the top of each column and represent the average of two separate experiments.

  • Figure 2.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 2.

    Reduction of constitutive and IL-6 induced STAT3 activation by 6-SHO in human prostate cancer cells. A–E, cell lines were cultured as indicated in Materials and Methods. Western blot analysis was performed to determine STAT3 status and level (pSTAT3Y705, pSTAT3S727, and total STAT3) in whole-cell lysates collected after the indicated treatments. A, cell lysates were prepared from untreated cultures of LNCaP, DU145, and PC-3 cells. B, LNCaP and DU145 cells were treated with 20 or 40 μmol/L 6-SHO and subjected to Western blot analysis. C, time course of the effect of 6-SHO on total and phosphorylated STAT3 in LNCaP and DU145 cells. Cells were treated with vehicle or 40 μmol/L 6-SHO for 1, 3, or 6 hours and Western blot analysis performed. D, LNCaP and DU145 cells were pretreated with 20 and 40 μmol/L 6-SHO for 2 hours followed by IL-6 for 30 minutes. E, LNCaP and DU145 cells were treated with vehicle or 40 μmol/L 6-SHO for 2 hours followed by IL-6 treatment for 0.5, 1, or 3 hours. F, DU145 cells were treated with vehicle or 40 μmol/L 6-SHO for 2 hours and the nuclear localization of STAT3 (red) was measured by immunofluorescence staining. G, LNCaP and DU145 cells were treated with vehicle or 40 μmol/L 6-SHO for 2 hours followed by IL-6 for 30 minutes. pJAK2 and pSrc was determined by Western blotting. Changes in relative band intensities (normalized to β-actin and total protein) for Western blot data are given at the top of each column. The results are significant (P < 0.05) where a decrease in phosphorylation is ≥40%.

  • Figure 3.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 3.

    Inhibition of constitutive and TNF-α induced NF-κB activity by 6-SHO in human prostate cancer cells. A, DU145 and PC-3 cells were treated with vehicle or 40 μmol/L 6-SHO and subjected to Western blot analyses. B, cells were treated with 20 and 40 μmol/L 6-SHO for 2 hours followed by TNF-α for 30 minutes and pNF-κBp65, NF-κBp65, and pIκBα levels were measured by Western blot analysis. Changes in relative band intensities (normalized to β-actin and total protein) for Western blot data are given at the top of each column. The results are significant (P < 0.05) where a decrease in phosphorylation is ≥ 40%. C, LNCaP and DU145 cells were treated with vehicle or 40 μmol/L 6-SHO for 2 hours followed by TNF-α for 30 minutes and the nuclear localization of NF-κBp65 (green) was measured by immunofluorescence staining.

  • Figure 4.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 4.

    Effect of 6-SHO on STAT3 and NF-κB targets in human prostate cancer cells. A, LNCaP and DU145 cells were treated with vehicle, 20 or 40 μmol/L 6-SHO and the level of survivin was measured by Western blot analysis. B, LNCaP and DU145 cells were treated with vehicle or 40 μmol/L 6-SHO for 1 or 3 hours and the level of cyclin D1, survivin, and cMyc was measured by Western blot analysis. C, LNCaP and DU145 cells were treated with vehicle or 40 μmol/L 6-SHO for 2 hours followed by IL-6 and the level of cyclin D1, survivin, and cMyc was measured by Western blot analysis. D, LNCaP, DU145, and PC-3 cells were treated with vehicle or 40 μmol/L 6-SHO for 2 hours followed by TNF-α and were subjected to Western blot analysis for cMyc protein. Changes in relative band intensities (normalized to β-actin) for Western blot data are given at the top of each column. The results are significant (P < 0.05) where a decrease in protein level is ≥ 40%. E, LNCaP and DU145 cells were treated with vehicle, 20 or 40 μmol/L 6-SHO for 24 hours. Gene expression for CCL5, IL-7, BCL2, BAX, p21, p27, SOCS1, and IRF-1 was measured by quantitative PCR. a, significantly different (P < 0.05) compared with the control group and b, compared with the other treated groups.

  • Figure 5.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 5.

    Effect of 6-SHO on mouse prostate cancer HMVP2 cells. A, HMVP2 cells were treated with the indicated concentrations of 6-SHO for 24, 48, and 72 hours and cell survival was measured by MTT assay. The data are presented as mean±SEM. B, HMVP2 cells were treated with vehicle or 40 μmol/L 6-SHO for 48 hours and apoptosis was measured by Annexin V staining. The data are presented as mean±SEM. C, HMVP2 cells were treated with 40 μmol/L 6-SHO for 30 and 60 minutes and Western blot analysis was performed for pSTAT3Tyr705, STAT3, and β-actin (top two); HMVP2 cells were treated with 20 and 40 μmol/L 6-SHO for 2 hours followed by IL-6 for 30 minutes and Western blot analysis was performed for pSTAT3Tyr705, STAT3, and β-actin (bottom two). D, HMVP2 cells were treated with vehicle or 40 μmol/L 6-SHO followed by TNF-α treatment for 30 minutes and Western blot analysis was performed for pNF-κBp65, NF-κBp65, and β-actin (top); HMVP2 cells were treated with 20 and 40 μmol/L 6-SHO for 2 hours followed by TNF-α for 30 minutes and Western blot analysis was performed for pNF-κBp65, NF-κBp65, pIκBα, and β-actin (bottom). E, HMVP2 cells were treated with vehicle, 20 or 40 μmol/L 6-SHO for 2 hours followed by IL-6 and the level of cyclin D1 was measured by Western blot analysis. F, HMVP2 cells were treated with vehicle or 40 μmol/L 6-SHO for 2 hours followed by TNF-α and the level of cMyc was measured by Western blot analysis. Changes in relative band intensities (normalized to β-actin and total protein) for Western blot data are given at the top of each column. The results are significant (P < 0.05) where a decrease in phosphorylation or protein level is ≥40%. G, LNCaP, DU145, PC-3, and HMVP2 cells were treated with the indicated concentrations of 6-PAR, 6-GIN, or 6-SHO for 48 hours and cell survival was measured by MTT assay. The data are presented as mean±SEM. a, significantly different (P < 0.05) compared with the control group and b, compared with the other treated groups of the same compound.

  • Figure 6.
    • Download figure
    • Open in new tab
    • Download powerpoint
    Figure 6.

    6-SHO reduces HMVP2 allograft tumor growth in vivo. Spheroids from HMVP2 cells were injected subcutaneously into the flank of male FVB mice. Two weeks after injection, mice were treated intraperitoneally with 6-SHO (50 or 100 mg/kg body weight, BW) every other day for the duration of the experiment. A, tumor volume is expressed as average tumor volume/mouse (mm3). B, tumor weight is presented as average tumor weight (mg)/mouse. C, average mouse BW (g) for each group. D, average feed consumption/mouse/day. Data are mean±SEM; n = 5 mice per group; *, P < 0.05 compared with the control group. Lysates of allograft tumor tissues were subjected to Western blot analysis for pSTAT3Tyr705 and STAT3 (E) and cyclinD1 and survivin (F) and β-actin was used as control for both sets of blots. Changes in relative band intensities (normalized to β-actin and total protein) for Western blot data are given at the top of each column. The results are significant (P < 0.05) where a decrease in phosphorylation or protein level is ≥40%.

Additional Files

  • Figures
  • Supplementary Data

    Files in this Data Supplement:

    • Supplementary Information - PDF - 191K, Tert-Butyldimethylsilyl ether-protected Zingerone.
    • Supplementary Figure 1 - PDF - 231K, Supplemental Figure 1. Reduction of constitutive and IL?6 induced STAT3 activation by 6?SHO in human PCa cells.
    • Supplementary Figure 2 - PDF - 119K, Supplemental Figure 2. G-SHO does not reduce survival of NMVP cells. Cells were treated with the indicated concentrations of G-SHO for 48 or 72 h and cell survival was measured by MTT assay. The data are presented as mean(plus/minus)SEM.
    • Supplementary Figure 3 - PDF - 248K, Supplemental Figure 3. Effects of ginger components, 6-GIN and 6-PAR, on human and mouse PCa cells.
    • Supplementary Figure 4 - PDF - 231K, Supplemental Figure 4. Effects of ginger components, 6-GIN and 6-PAR, on human and mouse PCa cells. DU145 and PC-3 cells were treated with 6-PAR, 6-GIN or 6-SHO followed by TNF-a and the levels of phospho IICBa, phospho NFICBp65 and NF-ICBp65 were measured by Western blot.
    • Supplementary Figure 5 - PDF - 267K, Supplemental Figure 5. Representative HMVP2 tumors from untreated mice.
PreviousNext
Back to top
Cancer Prevention Research: 7 (6)
June 2014
Volume 7, Issue 6
  • Table of Contents
  • Table of Contents (PDF)
  • About the Cover

Sign up for alerts

View this article with LENS

Open full page PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for sharing this Cancer Prevention Research article.

NOTE: We request your email address only to inform the recipient that it was you who recommended this article, and that it is not junk mail. We do not retain these email addresses.

Enter multiple addresses on separate lines or separate them with commas.
6-Shogaol from Dried Ginger Inhibits Growth of Prostate Cancer Cells Both In Vitro and In Vivo through Inhibition of STAT3 and NF-κB Signaling
(Your Name) has forwarded a page to you from Cancer Prevention Research
(Your Name) thought you would be interested in this article in Cancer Prevention Research.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
6-Shogaol from Dried Ginger Inhibits Growth of Prostate Cancer Cells Both In Vitro and In Vivo through Inhibition of STAT3 and NF-κB Signaling
Achinto Saha, Jorge Blando, Eric Silver, Linda Beltran, Jonathan Sessler and John DiGiovanni
Cancer Prev Res June 1 2014 (7) (6) 627-638; DOI: 10.1158/1940-6207.CAPR-13-0420

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
6-Shogaol from Dried Ginger Inhibits Growth of Prostate Cancer Cells Both In Vitro and In Vivo through Inhibition of STAT3 and NF-κB Signaling
Achinto Saha, Jorge Blando, Eric Silver, Linda Beltran, Jonathan Sessler and John DiGiovanni
Cancer Prev Res June 1 2014 (7) (6) 627-638; DOI: 10.1158/1940-6207.CAPR-13-0420
del.icio.us logo Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Jump to section

  • Article
    • Abstract
    • Introduction
    • Materials and Methods
    • Results
    • Discussion
    • Disclosure of Potential Conflicts of Interest
    • Authors' Contributions
    • Grant Support
    • Footnotes
    • References
  • Figures & Data
  • Info & Metrics
  • PDF
Advertisement

Related Articles

Cited By...

More in this TOC Section

  • mt-sDNA Specificity in 45–49 Year-Olds
  • Targeting CD40 and PD-1/PD-L1 Inhibits OPL Progression to OSCC
  • Revisiting a clinical diagnosis of NF1 for other syndromes
Show more Research Articles
  • Home
  • Alerts
  • Feedback
  • Privacy Policy
Facebook   Twitter   LinkedIn   YouTube   RSS

Articles

  • Online First
  • Current Issue
  • Past Issues

Info for

  • Authors
  • Subscribers
  • Advertisers
  • Librarians

About Cancer Prevention Research

  • About the Journal
  • Editorial Board
  • Permissions
  • Submit a Manuscript
AACR logo

Copyright © 2021 by the American Association for Cancer Research.

Cancer Prevention Research
eISSN: 1940-6215
ISSN: 1940-6207

Advertisement